Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Dev Ind Pharm. 2008 Sep;34(9):960-5. doi: 10.1080/03639040802154897 .

Review of the TAIFUN multidose dry powder inhaler technology.

Author information

1
PharmaForm LLC, Austin, TX 78758, USA.

Abstract

Although pressurized metered dose inhalers (pMDIs) currently constitute a majority of the market share in the inhalation market, dry powder inhaler (DPI) products have become increasingly popular due to their reliability and product performance. One such DPI is the TAIFUN inhaler that is a reservoir-based DPI system with the ability to produce consistent and uniform doses in vitro. Originally developed for the pulmonary delivery of salbutamol, the TAIFUN inhaler platform has since been used to develop a product for breakthrough cancer pain management using fentanyl citrate as the active drug. In vivo results show the TAIFUN inhaler is able to deliver a rapid onset of action and increased relative bioavailability compared with other fentanyl products currently on the market.

PMID:
18686086
DOI:
10.1080/03639040802154897
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center